Skip to main content

Table 1 Characteristics of cases of AML treated during pregnancy at our Istitution

From: Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature

Clinical case 1
Mother’s age, years 31
Gestational age, weeks 14
Induction chemotherapy -Induction: daunorubicin 50 mg/m2 (days 1, 3, 5) and cytosine arabinoside 3 g/m2 (days 1–5)
-Reinduction: fludarabine 30 mg/m2 (days 1–4), cytosine arabinoside 2 g/m2 (days 1–4) and idarubicin 12 mg/m2 (days 1–4)
Consolidation treatment -Cytosine arabinoside 3 g/m2 twice a day (days 1–3-5)
-Myeloablative sibling HSCT (conditioning regimen: busulfan 0,8 mg/kg three times a day days −9 -8 -7 -6 and cyclophosphamide 60 mg/kg days −3 -2)
Maternal outcome CR
Fetal outcome Surgical abortion at AML diagnosis
Delivery -
Clinical case 2
Mother’s age (years) 36
Gestational age (weeks) 32
Induction chemotherapy Daunorubicin 50 mg/m2 (days 1, 3, 5) and cytosine arabinoside 3 g/m2 (days 1–5)
Consolidation treatment -Cytosine arabinoside 3 g/m2 twice a day (days 1–4), daunorubicin 50 mg/m2 (days 5–6)
-Cytosine arabinoside 300 mg/m2 (days 1–5), daunorubicin 50 mg/m2 (days 1–2)
-Cytosine arabinoside 300 mg/m2 (days 1–5), etoposide 150 mg/m2 (days 1–3)
-Cytosine arabinoside 1 g/m2 twice a day (days 1, 3, 5)
-Autologous HSCT (conditioning regimen: cytosine arabinoside 3 g/m2 twice a day, cyclophosphamide 60 mg/kg twice a day for two days, 1000 cGy of total body irradiation)
Maternal outcome
Fetal outcome
Delivery
CR
Live birth, normal child
Cesarean at AML diagnosis
Clinical case 3
Mother’s age (years) 32
Gestational age (weeks) 26
Induction chemotherapy Cytosine arabinoside 2 g/m2 twice a day (days 1, 2, 8, 9) and idarubicin 18 mg/m2 (days 2, 3, 10) 6 weeks after delivery when MDS progressed to AML
Consolidation treatment -Cytosine arabinoside 100 mg/m2 (days 1–7), idarubicin 10 mg/m2 (days 1–3)
-Myeloablative sibling HSCT (conditioning regimen: busulfan 0.8 mg/kg three times a day, days −9 -8 -7 -6, cyclophosphamide 60 mg/kg, days −3 -2)
Maternal outcome
Fetal outcome
Delivery
CR
Live birth, normal child
Cesarean at 32 + 2 weeks after administration of betamethasone
Clinical case 4
Mother’s age (years) 34
Gestational age (weeks) 31
Induction chemotherapy Cytosine arabinoside 3 g/m2 (days 1–5) and daunorubicin 50 mg/m2 (days 2, 4, 5)
Consolidation treatment -Cytosine arabinoside 3 g/m2 twice a day (days 1–4), daunorubicin 50 mg/m2 (days 5–6)
−2 cycles of cytosine arabinoside 3 g/m2 twice a day (days 1–3-5)
Maternal outcome
Fetal outcome
Delivery
CR
Intrauterine fetal death
Cesarean at AML diagnosis
Clinical case 5
Mother’s age (years) 39
Gestational age (weeks) 24 + 5
Induction chemotherapy Cytosine arabinoside 100 mg/m2 (days 1–7) and daunorubicin 40 mg/m2 (days 1–3)
Consolidation treatment 4 cycles of cytosine arabinoside 3 g/m2 twice a day (days 1–3-5)
Maternal outcome CR; death for septic shock during the fourth and last consolidation cycle with high dose cytosine arabinoside
Fetal outcome
Delivery
Live birth, normal child
Cesarean at 30 weeks after administration of betamethasone
  1. CR complete remission, HSCT hematopoietic stem cell transplantation